Clinical trial · Interventional
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission
NCT00963521CI-TRIAL-00004815completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with acute myeloid leukemia in complete remission.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| therapeutic autologous dendritic cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Adverse events at 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of acute myelogenous leukemia (AML) * Myelomonocytic (M4) or monocytic (M5) subtype * In second complete remission (CR) or later following CR1 lasting ≤ 12 months after chemotherapy that may have included an intensification regimen followed by autologous transplantation * No (15;17) translocation * No AML M3 * HLA-A2 positivity * CD14 ≥ 20% on peripheral blood mononuclear cells * Circulating blasts ≥ 10 x 109/L (collected prior to chemotherapy) available * Must not be eligible for HLA-matched allogeneic transplantation * No progressive disease PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100% * Not pregnant or nursing * Fertile patients must use effective contraception * No contraindication to cytopheresis or chemotherapy * No HIV or HTLV positivity * No hepatitis B or C activation * No prior psychological disease * Not deprived of liberty and able to give consent * Must be able to speak and read French * No other cancer except for basal cell or cervical PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No concurrent participation in another clinical study
References
Publications (0)
Data not yet available
No reference posted for this study.